The authors propose the use of two new standardized measures of risk, the standardized lifetime risk and the standardized number of years of life lost. These measures maintain the advantages of standardized rates but are more readily understood without special training. In this paper, standardizing weights based on 1992 data from England and Wales are provided, and the new measures are illustrated with a variety of examples. The new standardized rates are useful for examining trends over time; for comparing the impact of various diseases on public health; and for comparing rates of a given disease in several different countries. The authors think it is far more informative to say that 41 out of every 1,000 women die of breast cancer than to say that the standardized mortality rate is 51 per 100,000 women per year. Am J Epidemiol 1999; 149:869-75. epidemiologic methods; incidence; mortality; risk; risk assessment Publications often quote death or disease rates per million. For instance, authors often make statements such as: "[Cervical cancer] is the eighth commonest cancer in women, with an annual incidence in the UK of 144 new cases for every million population" (1, p. 6). Even epidemiologists and biostatisticians find the phrase "144 new cases for every million population" hard to comprehend, so what is the lay public to make of it? Additionally, the crude incidence rates should not be used to compare different populations. The above authors meant "144 new cases per million females per year." That is, they do not include the whole population (males are excluded), but they do include young girls, in whom the incidence of cervical cancer is less than one per million. Crude rates can be used to compare different diseases in the same population, but they are not useful for comparing rates of the same disease in different populations or over time. To overcome this problem, agestandardized rates are used. That is, one calculates the rate that would have been observed had the age distribution in the population of interest matched that of some standard population.
Publications often quote death or disease rates per million. For instance, authors often make statements such as: "[Cervical cancer] is the eighth commonest cancer in women, with an annual incidence in the UK of 144 new cases for every million population" (1, p. 6). Even epidemiologists and biostatisticians find the phrase "144 new cases for every million population" hard to comprehend, so what is the lay public to make of it? Additionally, the crude incidence rates should not be used to compare different populations. The above authors meant "144 new cases per million females per year." That is, they do not include the whole population (males are excluded), but they do include young girls, in whom the incidence of cervical cancer is less than one per million. Crude rates can be used to compare different diseases in the same population, but they are not useful for comparing rates of the same disease in different populations or over time. To overcome this problem, agestandardized rates are used. That is, one calculates the rate that would have been observed had the age distribution in the population of interest matched that of some standard population.
For most people, it is easier to relate to the lifetime risk of getting a particular disease than to the annual rate of incidence of that disease. One might ask, "What is the risk of a 20-year-old woman's getting cervical cancer at some stage in her life?" Of course, we can't know the exact answer to such a question, because it depends on what happens to life expectancy and to the incidence of cervical cancer over the next 70 years; and we are not generally interested in the lifetime risk of cervical cancer for women born 90 years ago. The standard method for estimating lifetime risk of a disease assumes that all future incidence and mortality rates will match those of the current year (2). It is a fiction which is reasonable so long as one realizes what is meant by "lifetime risk." The problem is that when we adjust for mortality, the lifetime risk of a disease will be greater in a country with greater life expectancy than in one with lower life expectancy, even if the age-specific incidence rates are identical in the two countries. Similarly, if life expectancy improves over time, the lifetime risk will increase even if the incidence rates do not change.
The cumulative rate (3) provides a partial solution. It is simply the sum of the annual age-specific rates. It has the advantage of dispensing with the selection of a standard population, and it is straightforward to convert from cumulative rates to cumulative risks by means of the formula P = 1 -exp(-A), in which A is the cumulative rate and P is the cumulative risk or probability. When A is small (e.g., <0.05), P ~ A, so the cumulative rate can roughly be thought of as the cumulative probability. Thus, for instance, the cumulative rate from birth to age 74 years can be used to calculate the cumulative risk over that period, which can roughly be thought of as the lifetime risk when the cumulative rate is small.
METHODS
What we propose here is a measure that would be called a "standardized lifetime risk" but is, more formally, a "standardized cumulative risk." Let 5/ be the proportion of the standard sex-specific population who survive until age i, and let R, be the age-specific rate of the disease of interest in a given population and a particular calendar year. Then the standardized Lifetime risk for that population and calendar year is defined to be the weighted sum of age-specific rates:
(1) (Here we assume that the contribution from people living to >100 years is negligible. Note also that if one is using 5-year age groups, the formula would be 20 (2) where the subscript; indexes the different age groups.)
Additionally, one might calculate a standardized "number of years of life lost" due to death from a particular disease as follows: The ratio of the standardized number of years of Life lost to the standardized Lifetime risk gives the standardized mean number of years lost by an individual who dies from that specific cause:
It is simply a weighted average of the standard life expectancies at each age with weights equal to the standardized probability of dying from the disease at a given age.
A slightly different formula should be used when the data are considered in 5-year age groups. In that case, define A ( recursively starting with the oldest age group: A M = SjJ{\ -Sj,,), where s is the probability of surviving for 1 year given that one is in the jth age group (i.e., s equals 1 minus the aLL-cause mortality rate, d). 
-
Our proposal is a weighted cumulative rate with weights that are independent of the cause of death. Thus, our definition of lifetime risk does not adjust the standardizing weights (which are derived from allcause mortality) for the numbers of people dying from the specific cause. One could argue, for instance, that the lifetime risk of cardiovascular disease death should be much larger than is estimated by our method, since, if people did not die from cardiovascular disease in their 40s and 50s, more would live into their 60s and 70s and the numbers dying from cardiovascular disease at those ages would be greater. We do not use that reasoning in this paper. Similarly, the number of years of life lost due to death from a particular disease will be underestimated by the method proposed here. Not only are the 5 y 's not adjusted upwards but the residual Life expectancies are also unchanged and so do not reflect the greater Life expectancy that would result from removing a cause of death. Thus, for instance, one could argue that the number of years of life lost due to all-cause mortality is infinite, for if one removed all causes of death, people would live forever. The effect of these adjustments (i.e., of replacing s by s y + Rp on breast cancer mortality is to increase the standardized lifetime risk from 40.9 per 1,000 female births to 42.0 per 1,000 and the standardized years of life lost from 769 per 1,000 women to 792 per 1,000. Similarly, the standardized lifetime risk of death due to ischemic heart disease in men increases from 25.0 percent to 32.9 percent and the years of life lost increase from 3,037 per 1,000 male births to 4,169 per 1,000 when adjusting the weights for the component of all-cause mortality that is due to ischemic heart disease. The effect on less common causes of death is minimal.
A method for estimating the standard error of the new measures is described in the Appendix.
In this paper, we prefer to estimate the all-cause mortality rate as a smooth function of age in order to estimate Si and A, for each year from birth to age 100. Table  1 provides standard survival curves and the corresponding residual Life expectancies for men and women, based on 1992 mortality data from England and Wales (4). These standards are used throughout this paper. 
RESULTS
We first illustrate these methods using cervical cancer data. Table 2 gives age-specific incidence rates and mortality rates for cervical cancer in England and Wales from 1980 and 1994, respectively (5, 6) . We have provided these data to enable interested readers to verify our calculations. Use of the above formulae with the survival and life expectancy for each 5-year age group taken to be that of the middle year (e.g., age 57 years for the group aged 55-59) gives a standardized lifetime risk of cervical cancer of 12.9 per 1,000 female births and a standardized lifetime risk of dying from cervical cancer of 4.3 per 1,000. The standardized number of years of life lost due to cervical cancer is 96.0 per 1,000 female births. All of these quantities were calculated using the standard survival curve from 1992 (table 1) .
Next we consider the use of the proposed measures to describe trends in cervical cancer mortality in England and Wales. Figures 1 and 2 plot the standardized lifetime risk of dying from cervical cancer ( figure  1 ) and the standardized years of life lost due to cervical cancer mortality (figure 2) against each year between 1950 and 1994. The age-standardized mortality rate is graphed in figure 3 for comparison. Note how the recent fall in the standardized years of life lost is even more impressive than the fall in standardized lifetime risk. The curve in figure 3 gives the same qualitative impression of falling mortality as does figure 1, but the numeric values of the standardized lifetime risk are much easier to relate to than those of the age-standardized risk. For instance, between 1960 and 1980, the standardized lifetime risk fell by 2.9 per 1,000 female births. Over the same period, the agestandardized rate changed by 4.4 per 100,000 women.
Until recently, mortality and cancer incidence data were not subdivided by age beyond 85 years. The effect of using a single rate for cervical cancer for ages >85 years rather than separate rates for ages 85-89, 90-94, and >95 years was to change the standardized measures by less than 0.1 percent of their values.
Another use of standardized rates is to compare the public health impacts of various diseases. Table 3 gives the standardized lifetime risk of dying from each of the main causes of death and the standardized number of years of life lost based on disease-specific mortality rates in England and Wales from 1994 (6) and the standardized survival rates from 1992 (table 1) . We also present the standardized mean number of years lost by an individual who dies from each of the different causes of death. Notice how this is less than 10 years for prostate cancer and pneumonia, which are normally fatal only in old age, but over 20 years (in women) and over 30 years (in men) for deaths due to injury and poisoning. Once again, although the age-standardized rates (not shown) would have permitted some comparison between different causes of death similar to those comparisons using the standardized lifetime risk, the absolute value of the latter is more informative. Furthermore, the additional use of the standardized mean number of years lost enables one to distinguish between mortality in the young, the middle-aged, and the old. On the basis of incidence data obtained from the International Agency for Research on Cancer (7), table 4 gives the standardized lifetime risk of cervical cancer per 1,000 female births in various geographic areas and among ethnic groups within geographic areas. Notice, in particular, the difference in the standardized numbers of years lost due to cervical cancer (per 1,000 female births) between white women in the United States and women in Shanghai, People's Republic of China, despite the similar standardized lifetime risks. The reason for the much lower number of years of life lost in China is that the disease in Shanghai is extremely rare among women under the age of 55 years. pares the age-specific incidence rates of cervical cancer in Shanghai women with those in US white women. Note that consideration of traditional measures such as the age-standardized rate and the cumulative rate up to age 74 years does not flag the difference between US white women and Shanghai women nearly so clearly. In all populations in table 4, the cumulative rate is (very) approximately 10 percent of the agestandardized rate. Thus, the two measures are in no sense complementary in this example.
DISCUSSION
The proposed new measures are easy to calculate and are straightforward to interpret They are also easy for the public to understand. They have an advantage over other measures of lifetime risk, in that they are not dependent on changing or differing rates of mortality from other causes. Thus, they are suitable for comparing 1) different diseases in the same population, 2) the same disease in different populations, and 3) trends in the 
